Navigation Links
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Date:1/14/2008

nsitivity to Vidaza or mannitol and in patients with advanced malignant hepatic tumors.

In clinical studies, the most commonly occurring adverse reactions by SC route were nausea (70.5%), anemia (69.5%), thrombocytopenia (65.5%), vomiting (54.1%), pyrexia (51.8%), leukopenia (48.2%), diarrhea (36.4%), fatigue (35.9%), injection site erythema (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile neutropenia (16.4%), myalgia (15.9%), injection site reaction (13.6%), aggravated fatigue (12.7%) and malaise (10.9%). The most common adverse reactions by IV route also included petechiae (45.8%), rigors (35.4%), weakness (35.4%) and hypokalemia (31.3%).

Because treatment with Vidaza is associated with neutropenia and thrombocytopenia, complete blood counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each dosing cycle. Because Vidaza is potentially hepatotoxic in patients with severe pre-existing hepatic impairment, caution is needed in patients with liver disease. In addition, Vidaza and its metabolites are substantially excreted by the kidneys and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, it may be useful to monitor renal function.

Vidaza may cause fetal harm. While receiving treatment with Vidaza, women of childbearing potential should avoid becoming pregnant, and men should avoid fathering a child. In addition, women treated with Vidaza should not nurse.

About Pharmion

Pharmion is a leading global oncology company uniquely focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including t
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
2. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
3. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
4. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
5. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...KLIN, Mass., Nov. 26 PLC...d today that it has received full approval from th...U.S. pivotal trial to study the effectiveness of t... therapy in the prevention of Contrast-Induced Nep...LC,s request to expand their investigation from th...
(Date:11/25/2008)...re-FirstCall/ -- Poniard,Pharmaceuticals, Inc. (N...ed on,innovative oncology therapies, announced to...ves for its preclinical research programs in order...he clinical development of picoplatin,its lead p...rcialization of,picoplatin in the treatment of sm...
(Date:11/24/2008)...no,s Pizza (NYSE: DPZ ), the,recognized world l...ugh for,the kids of St. Jude Children,s Research ...g campaign. Domino,s customers will have the oppor... benefit the children of St. Jude.,Donations can ...ing online at, www.dominos.com . The campaign beg...
(Date:11/24/2008)...l/ -- Schering-Plough Corporation (NYSE: SGP ) t...ctive adenosine2a receptor antagonist, met the pri...patients suffering from moderate to severe Parkins...bnormal involuntary movements (dyskinesias). The ...s 2008 R&D Update meeting being hosted for ana...
Breaking Medicine Technology:PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008 6188 1FierceBiotech Names NanoBio Corporation as One of the Fierce 15 Biotech Companies of 2008 6188 2New cardiovascular score developed to improve heart attack and stroke detection 22648 1New cardiovascular score developed to improve heart attack and stroke detection 22648 23rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide Inc 22643 13rd Annual Conference on Pain Jointly Sponsored By Rehabilitation Institute of Chicago and MediCom Worldwide Inc 22643 2Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition 28TM 29 22638 1Heart Disease and Diabetes Finally Meet Their Match With Delicious New Snack Bars From WatchDog Nutrition 28TM 29 22638 2
...cified subset analyses of progression-free surviva...ate a reduction in,relative risk of disease progre...alyses included prior Taxotere use,geographies, a...une 04, 2007 /PRNewswire-FirstCall/ -- Pharmion,Co...resentation of,additional data from the double-bli...
...., June 04, 2007 /PRNewswire-FirstCall/ -- Boston,...ion of an article,in the Journal of of Cardiology ...hich evaluates the Company,s second-generation,TAX...em. The,article in the April 24 edition of JACC co...bailout rate of the TAXUS Liberte Stent,system com...
Other Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 2Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 3Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 4
(Date:12/1/2008)...wire-FirstCall/ -- The Ensign Group, Inc.,(Nasdaq... Rehabilitation Center in,Pocatello, Idaho has su... and,Medicaid Services, Special Focus program. ,...h/20071213/LATH168LOGO ) , A clinical team ...llo Care,& Rehabilitation Center, completed t...
(Date:12/1/2008)..., at Memorial Sloan-Kettering Cancer Center, New Y... expression of genes for therapeutic purposes, and... in mice. , Small, noncoding RNA molecules known... expression. In the study, the miRNA miR-181a was ...ne cells known as T cells at different stages of t...
(Date:12/1/2008)...irstCall/ -- ViroPharma Incorporated,(Nasdaq: V... supplemental,Biologics License Application (sBLA...for Cinryze(TM) C1 Inhibitor (human) as a treatmen...). , The sBLA is based on a re-analysis and...e treatment study of Cinryze and interim data from...
(Date:12/1/2008)...ty illnesses common, study shows , , MO...ders are common among young adults in the United S... , To reach this finding, U.S. researchers anal...9 to 25, who took part in the National Epidemiolog...The study found that 45.8 percent of the 2,188 col...
Breaking Medicine News(10 mins):Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 2Health News:The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 2Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 3Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 4Health News:ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema 5Health News:Few Young Adults Seek Treatment for Psych Disorders 2
...der unsanitary and freezing conditions in the coun...e and shell marine products.// The National Instit...bad conducted a study which reveals that many amon...n working in fish processing units are predominant...
...d that more devastating earthquakes are likely to ...50 years. // They will inflict far greater damage ... in Pakistan. Roger Bilham who has been working i... the past two months, said that a huge amount of e...
... Journal of Psychiatry that antidepressant drugs d...rather decrease the suicide risk. The article also...nt drugs should be closely monitored to find their... dosage can cause adverse conditions. The resea...
...nd news media to increase the awareness about chil...// to increase child survival. The Lancet reports ...achievable, Millennium Development Goal – 4 (MDG) ...en below the age of 5 and MDG-5 wants a reduction ...
Other Medicine News:Health News:Unregulated Fish Industry Harms Health Of Women 2Health News:More Severe Earthquakes May Hit Kashmir In Future 2
Clinician's Pocket Drug Reference 2005 includes key elements of commonly used medications that are essential information for both the student and practicing physician.
AHFS Patient Drug Information gives you a single source for providing important information and instructions for patients on dosing, precautions, possible side effects and interactions, and more.
Containing more than 600 full drug monographs, plus abbreviated monographs for combination drugs, orphan drugs and AIDS drugs in development, A to Z Drug Facts provides up-to-date information on more
Provides instant access to reliable information on herbs, minerals, vitamins, amino acids, probiotics, enzymes, over-the-counter hormones, and other dietary supplements commonly used by consumers.
Medicine Products: